Sifting through countless of stocks in the Health Care Providers & Services industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Hims & Hers Health, Inc. or Jazz Pharmaceuticals plc because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Hims & Hers Health, Inc. and Jazz Pharmaceuticals plc compare based on key financial metrics to determine which better meets your investment needs.

About Hims & Hers Health, Inc. and Jazz Pharmaceuticals plc

Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, Australia, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides personalized health and wellness products; over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, skincare, sexual health and wellness, and hair care under the Hims & Hers brand name; and laboratory testing services to measure a set of biomarkers. Additionally, it offers medical consultation, post-consultation support services, and delivery of laboratory testing results services. Further, the company provides treatments and products for various chronic conditions related to hormone health, weight loss, dermatology, and mental health. The company offers its products through retail partnerships, in stores, and online. The company was formerly known as Hims, Inc. and changed its name to Hims & Hers Health, Inc. in January 2021. The company was founded in 2017 and is based in San Francisco, California.

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., Werewolf Therapeutics, Inc; and AbCellera Biologics Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.

Latest Health Care Providers & Services and Hims & Hers Health, Inc., Jazz Pharmaceuticals plc Stock News

As of October 9, 2026, Hims & Hers Health, Inc. had a $7.2 billion market capitalization, compared to the Health Care Providers & Services median of $1.6 million. Hims & Hers Health, Inc.’s stock is down 4.8% in 2026, up 6.6% in the previous five trading days and down 46.85% in the past year.

Currently, Hims & Hers Health, Inc. does not have a price-earnings ratio. Hims & Hers Health, Inc.’s trailing 12-month revenue is $2.6 billion with a -5.5% net profit margin. Year-over-year quarterly sales growth most recently was 38.3%. Analysts expect adjusted earnings to reach $0.282 per share for the current fiscal year. Hims & Hers Health, Inc. does not currently pay a dividend.

As of October 9, 2026, Jazz Pharmaceuticals plc had a $14.2 billion market cap, putting it in the 83rd percentile of all stocks. Jazz Pharmaceuticals plc’s stock is up 28.5% in 2026, down 7.3% in the previous five trading days and up 58.53% in the past year.

Currently, Jazz Pharmaceuticals plc’s price-earnings ratio is 14.9. Jazz Pharmaceuticals plc’s trailing 12-month revenue is $4.6 billion with a 20.4% net profit margin. Year-over-year quarterly sales growth most recently was 15.5%. Analysts expect adjusted earnings to reach $21.647 per share for the current fiscal year. Jazz Pharmaceuticals plc does not currently pay a dividend.

How We Compare Hims & Hers Health, Inc. and Jazz Pharmaceuticals plc Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Hims & Hers Health, Inc. and Jazz Pharmaceuticals plc’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Hims & Hers Health, Inc. and Jazz Pharmaceuticals plc’s Quality Grades

Company	Ticker	Quality
Hims & Hers Health, Inc.	HIMS	D
Jazz Pharmaceuticals plc	JAZZ	A

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Hims & Hers Health, Inc. has a Quality Score of 34, which is Weak. Jazz Pharmaceuticals plc has a Quality Score of 96, which is Very Strong.

The Quality Grade Winner: Jazz Pharmaceuticals plc

As you can clearly see from the Quality Grade breakdown above, Jazz Pharmaceuticals plc has a better overall quality grade than Hims & Hers Health, Inc.. For investors who are looking for companies with higher quality than others in the same industry, Jazz Pharmaceuticals plc could be a good stock to add to their portfolios. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Hims & Hers Health, Inc. and Jazz Pharmaceuticals plc’s Momentum Grades

Company	Ticker	Momentum
Hims & Hers Health, Inc.	HIMS	D
Jazz Pharmaceuticals plc	JAZZ	B

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Hims & Hers Health, Inc. has a Momentum Score of 26, which is Weak. Jazz Pharmaceuticals plc has a Momentum Score of 76, which is Strong.

The Momentum Grade Winner: Jazz Pharmaceuticals plc

As you can clearly see from the Momentum Grade breakdown above, Jazz Pharmaceuticals plc is considered to have stronger momentum compared to Hims & Hers Health, Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Jazz Pharmaceuticals plc could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Hims & Hers Health, Inc. and Jazz Pharmaceuticals plc’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Hims & Hers Health, Inc.	HIMS	F
Jazz Pharmaceuticals plc	JAZZ	D

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Hims & Hers Health, Inc. has a Earnings Estimate Score of 8, which is Very Negative. Jazz Pharmaceuticals plc has a Earnings Estimate Score of 27, which is Negative.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither Hims & Hers Health, Inc. or Jazz Pharmaceuticals plc has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Hims & Hers Health, Inc. or Jazz Pharmaceuticals plc is the better investment when it comes to estimate revisions.

Other Hims & Hers Health, Inc. and Jazz Pharmaceuticals plc Grades

In addition to Momentum, Estimate Revisions and Quality, A+ Investor also provides grades for Value and Growth.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Hims & Hers Health, Inc. and Jazz Pharmaceuticals plc pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Hims & Hers Health, Inc. or Jazz Pharmaceuticals plc Stock?

Overall, Hims & Hers Health, Inc. stock has a Momentum Score of 26, Estimate Revisions Score of 8 and Quality Score of 34.

Jazz Pharmaceuticals plc stock has a Momentum Score of 76, Estimate Revisions Score of 27 and Quality Score of 96.

Comparing Hims & Hers Health, Inc. and Jazz Pharmaceuticals plc’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.